Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk presented new Phase 3 ESSENCE data on semaglutide’s liver safety and efficacy at EASL 2026.
The update includes the first dedicated results in menopausal women and Japanese patients with MASH.
Findings suggest a consistent hepatic safety profile across these historically underrepresented groups.
Novo Nordisk (CPSE:NOVO B) is drawing fresh attention with these MASH data at a time when its share price stands at DKK288.4. The stock is up 11.8% over the past 30 days but remains down 12.7% year to date and down 33.9% over the past year, while still showing a 31.3% gain over five years. For investors, that mix of near term strength and longer term volatility is the backdrop for interpreting this new clinical update.
Semaglutide’s extended evidence in liver disease broadens the drug’s clinical story beyond obesity and diabetes into a large, underdiagnosed condition. As regulators, clinicians and payers weigh treatment options for MASH, the depth and quality of subgroup data, including in menopausal women and Japanese patients, may influence how widely semaglutide is used across different patient groups over time.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at May 2026
We’ve flagged 4 risks for Novo Nordisk. See which could impact your investment.
Quick Assessment
⚖️ Price vs Analyst Target: At DKK288.4, the stock trades about 6.4% below the DKK307.99 analyst target, so it sits slightly under consensus.
✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 58.9% below fair value, which is a large discount.
✅ Recent Momentum: The stock is up 11.8% over the last 30 days, suggesting traders are responding positively to recent developments.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to the Simply Wall St company report for the latest analysis of Novo Nordisk’s Fair Value.
Key Considerations
📊 The ESSENCE MASH data, including menopausal women and Japanese patients, supports a more complete clinical profile for semaglutide in liver disease.
📊 Watch for any updates from regulators, treatment guideline bodies and payers on how this subgroup evidence influences adoption in MASH care.
⚠️ The company still carries 4 flagged risks, including dividend coverage concerns, share price volatility and a high level of debt.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can visit the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com